Amycretin: The Oral Amylin/GLP-1 Combo Explained
Guide to amycretin, Novo Nordisk's oral dual amylin and GLP-1 receptor agonist. Learn about its mechanism, early clinical data showing impressive weight loss, and what it could mean for the future of oral obesity treatment.
More on Pipeline Drugs
The Holy Grail: Dual-Action in a Pill
Amycretin represents what many consider the ultimate goal in obesity drug development: combining the proven benefits of multiple hormone pathways into a single oral medication. If successful, amycretin would deliver CagriSema-level efficacy (potentially 20%+ weight loss) without requiring injections — a combination that could transform obesity treatment globally.
The molecule itself is a single peptide engineered to activate both amylin receptors and GLP-1 receptors. Rather than mixing two separate drugs (as CagriSema does), amycretin is designed from the molecular level to interact with both receptor systems. This elegant approach simplifies manufacturing and may offer pharmacokinetic advantages. Combined with Novo Nordisk's proprietary SNAC oral absorption technology, the goal is to deliver this dual-action peptide as a daily pill.
Why the Amylin Pathway Matters
Amylin is a hormone co-secreted with insulin by pancreatic beta cells after meals. In a healthy metabolism, amylin provides important post-meal signals:
- Satiety signaling: Amylin acts on the area postrema in the brainstem to produce feelings of fullness after eating.
- Gastric emptying: Like GLP-1, amylin slows the rate at which food leaves the stomach, extending feelings of fullness.
- Glucagon suppression: Amylin reduces inappropriate glucagon secretion after meals, helping maintain stable blood sugar.
- Distinct brain pathways: Critically, amylin activates appetite-suppressing neurons in areas of the brain that are different from those targeted by GLP-1. This means the two hormones provide additive appetite suppression rather than redundant signaling.
In obese individuals, amylin signaling is often dysfunctional, contributing to excessive appetite and poor meal-related satiety. Restoring robust amylin signaling alongside GLP-1 activation creates a more complete correction of the hormonal imbalances that drive overeating. Learn about current GLP-1 treatment options.
Early Clinical Data
Phase 1/2 Headline Results
In early-stage trials, amycretin demonstrated approximately 10-13% body weight loss in just 12 weeks at the highest tested doses. For context, semaglutide typically produces 5-7% weight loss at 12 weeks. If this trajectory continues over a full 68-week treatment period, amycretin could potentially deliver weight loss exceeding current options.
It is important to note that early-phase results can be optimistic due to smaller sample sizes and patient selection. Phase 2 and Phase 3 trials with larger, more diverse populations will provide a more accurate picture of real-world efficacy. The weight loss trajectory may also flatten over time, as occurs with all obesity medications.
Side effects in early trials were consistent with the GLP-1 class: nausea, vomiting, and diarrhea were most common. The severity and frequency will be better characterized in larger studies. Novo Nordisk is optimizing the titration schedule to minimize GI side effects during the dose escalation period.
Amycretin vs Other Pipeline Drugs
vs. CagriSema (Injectable Amylin + GLP-1)
Same pathway targets, different delivery. CagriSema is a weekly injection with Phase 3 data showing 22-25% weight loss. Amycretin aims to achieve similar results orally. If efficacy is comparable, patient preference for pills versus injections would drive the choice. CagriSema is closer to market approval.
vs. Orforglipron (Oral GLP-1 Only)
Orforglipron is a small molecule (non-peptide) oral GLP-1 agonist from Eli Lilly with approximately 14-15% weight loss in Phase 2. Amycretin adds the amylin pathway for potentially greater efficacy but is a peptide requiring SNAC technology and fasting. Orforglipron's convenience advantage may offset amycretin's efficacy advantage for some patients.
vs. Oral Semaglutide 50mg
Both use Novo Nordisk's SNAC oral technology. Oral semaglutide 50mg produces approximately 15-17% weight loss through GLP-1 only. Amycretin adds amylin receptor activation for potentially greater weight loss. Amycretin could be positioned as Novo's premium oral option when it reaches market. See how these medications work.
What to Watch For
As amycretin progresses through clinical development, key milestones to watch include:
- Phase 2 full results: Complete data from larger, longer Phase 2 studies will reveal whether the impressive early weight loss trajectory is sustained.
- Phase 3 trial initiation: The design and endpoints of Phase 3 trials will signal Novo Nordisk's confidence and regulatory strategy.
- Head-to-head comparisons: Any data comparing amycretin to CagriSema or other competitors would be highly informative.
- Tolerability data: Whether the dual mechanism creates more or different side effects than GLP-1 alone is an important safety question.
- Manufacturing scale-up: Oral peptide manufacturing at the scale needed for a global obesity treatment is a significant challenge that could affect availability timelines.
Medical Disclaimer: This article discusses a medication in early clinical development. Amycretin has not been approved by the FDA and may not ultimately receive approval. Early clinical results may not predict final outcomes. Consult your healthcare provider about currently available treatment options.
Frequently Asked Questions
What is amycretin?
Amycretin is an oral once-daily medication being developed by Novo Nordisk that activates both the amylin and GLP-1 receptors in a single molecule. Unlike CagriSema (which combines two separate molecules in an injection), amycretin is a single co-agonist peptide designed to work as a pill, using Novo Nordisk's oral peptide delivery technology.
How much weight loss does amycretin produce?
Early Phase 1/2 data showed amycretin producing approximately 10-13% body weight loss in just 12 weeks, an unusually rapid rate that suggests potentially higher total weight loss over a full treatment course. These early results generated significant excitement, though Phase 2/3 data over longer periods is needed to confirm the trajectory.
When will amycretin be available?
Amycretin is still in early-to-mid-stage clinical development. Novo Nordisk is conducting additional Phase 2 studies, with Phase 3 trials planned to follow. Realistic availability is likely 2028 or later, depending on clinical trial results and regulatory review timelines.
How does amycretin compare to CagriSema?
Both target amylin and GLP-1 pathways, but amycretin is an oral pill while CagriSema is a weekly injection combining two separate molecules. Amycretin's oral format is a major convenience advantage. If amycretin can match CagriSema's efficacy (22-25% weight loss) in an oral form, it would represent a significant advance in obesity treatment.
Does amycretin require fasting like oral semaglutide?
As a peptide using Novo Nordisk's SNAC-based oral delivery technology, amycretin likely has similar dosing requirements to oral semaglutide — meaning it should be taken on an empty stomach with limited water. However, final dosing instructions will depend on Phase 3 trial protocols and FDA labeling decisions.
Start GLP-1 Treatment Today
Proven, effective GLP-1 therapy is available now while next-gen drugs develop.
Get Started TodaySources & References
- Wilding JPH et al. Once-Weekly Semaglutide in Adults with Overweight or Obesity. NEJM 2021;384:989-1002.
- Jastreboff AM et al. Tirzepatide Once Weekly for the Treatment of Obesity. NEJM 2022;387:205-216.
- Lincoff AM et al. Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes. NEJM 2023;389:2221-2232.
- FDA Prescribing Information for Wegovy (semaglutide) and Zepbound (tirzepatide).